Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34results about How to "Enhance mobilization" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods of using G-CSF mobilized C-Kit+ cells in the production of embryoid body-like cell clusters for tissue repair and in the treatment of cardiac myopathy
InactiveUS20050186182A1Enhance mobilizationInhibition of differentiationBiocideMammal material medical ingredientsMyopathyTissue repair
The present invention relates to methods of using granulocyte colony stimulating factor (G-CSF) polypeptide, alone and in conjunction with stromal cell derived factor (SDF-1) polypeptide, to increase the mobilization of c-Kit+ stem cells in the blood, bone marrow, tissue, heart or other organs for the subsequent production of embryoid body-like cell clusters. These embryoid body-like cell clusters can be used for cell replacement therapy, for the treatment of cardiac myopathy and other diseases and disorders, and for screening agents that drive or inhibit differentiation and proliferation.
Owner:AMGEN INC
Methods and compositions for modulating the mobilization of stem cells
InactiveUS20070190023A1Enhance mobilizationPrevent egressBiocidePeptide/protein ingredientsDiseaseCXCR4
Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells from the bone marrow to the peripheral blood are disclosed. In particular, the invention relates to the use of adrenergic agonists that act in concert with a mobilization compound or agent. The mobilization agent(s) may act to decrease the expression or function of the chemokine, CXCL12, or may act to block or antagonize CXCR4. The invention also relates to methods of using these compounds or agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells is necessary for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating the symptoms associated with such diseases, disabilities or conditions. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed.
Owner:MT SINAI SCHOOL OF MEDICINE
Therapeutic, fitness, and sports enhancement device
ActiveUS7918774B2Maximize mobilizationEnhance distensibilityCeramic shaping apparatusRoller massageUltimate tensile strengthBiomedical engineering
A therapeutic, fitness, and sports enhancement device including a cylindrically shaped body having a plurality of shaped projections configured to enhance mobilization of soft tissue and optimize body core strength and balance training.
Owner:PERFORMANCE SOLUTIONS
Compositions comprising E-selectin antagonists and uses therefor
ActiveUS9254322B2Stimulating and enhancing hematopoiesisAvoid adjustmentPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsProgenitorSurgery
This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and / or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
Owner:THE UNIV OF QUEENSLAND
Therapeutic, fitness, and sports enhancement device
ActiveUS8002682B2Maximize mobilizationEffectively mobilizesRoller massageDomestic articlesHuman bodyVolumetric Mass Density
A therapeutic, fitness, and sports enhancement device comprising a cylindrically shaped body having a predetermined density and predetermined diameter including a plurality of projections of a predetermined shape. One or more of the predetermined density, the predetermined diameter, and predetermined shape are configured to enhance mobilization of one or more small soft tissue structures of the human body.
Owner:PERFORMANCE SOLUTIONS
Crosslinking of swellable polymer with pei
InactiveUS20140144628A1Stable and labile crosslinkersResist erosionFluid removalFlushingFlocculationPapermaking
The invention is directed to stable and labile crosslinked water swellable polymeric microparticles that can be further gelled, methods for making same, and their various uses in the hygiene and medical arts, gel electrophoresis, packaging, agriculture, the cable industry, information technology, in the food industry, papermaking, use as flocculation aids, and the like. More particularly, the invention relates to a composition comprising expandable polymeric microparticles having labile crosslinkers and stable crosslinkers, said microparticle mixed with a fluid and an unreacted tertiary crosslinker comprising PEI or other polyamine based tertiary crosslinker that is capable of further crosslinking the microparticle on degradation of the labile crosslinker and swelling of the particle, so as to form a stable gel. A particularly important use is as an injection fluid in petroleum production, where the expandable polymeric microparticles are injected into a well and when the heat and / or pH of the well cause degradation of the labile crosslinker and when the microparticle expands, the tertiary crosslinker crosslinks the polymer to form a stable gel, thus diverting water to lower permeability regions and improving oil recovery.
Owner:UNIVERSITY OF KANSAS +1
Therapeutic, fitness, and sports enhancement device
ActiveUS20090131234A1Enhance mobilizationMaximize mobilizationRoller massageDomestic articlesBiomedical engineeringHuman body
A therapeutic, fitness, and sports enhancement device comprising a cylindrically shaped body having a predetermined density and predetermined diameter including a plurality of projections of a predetermined shape. One or more of the predetermined density, the predetermined diameter, and predetermined shape are configured to enhance mobilization of one or more small soft tissue structures of the human body.
Owner:PERFORMANCE SOLUTIONS
Structured Lipid Compositions And Methods Of Formulation Thereof
ActiveUS20090123634A1High energyIncrease valueFood preparationEdible oils/fats with aqeous phaseTriglycerideWeight management
Lipid compositions comprising specific mixtures of edible synthetic triglycerides are provided that are useful in formulating food products having highly desirable dietary benefits. The novel lipid compositions allow simultaneous access to highly desirable dietary benefits such as delivery of calorie reduction, weight management, health benefits, or any combination thereof, and they also may be formulated trans-fatty acid free.
Owner:INTERCONTINENTAL GREAT BRANDS LLC
Treatment and prophylaxis
ActiveUS20110020270A1Stimulating and enhancing hematopoiesisAvoid adjustmentOrganic active ingredientsPeptide/protein ingredientsDiseaseWhite blood cell
This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and / or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
Owner:THE UNIV OF QUEENSLAND
Methods and compositions for modulating the mobilization of stem cells
InactiveUS7939057B2Enhance mobilizationPrevent egressBiocidePeptide/protein ingredientsDiseaseAdrenergic receptor agonists
Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells from the bone marrow to the peripheral blood are disclosed. In particular, the invention relates to the use of adrenergic agonists that act in concert with a mobilization compound or agent. The mobilization agent(s) may act to decrease the expression or function of the chemokine, CXCL12, or may act to block or antagonize CXCR4. The invention also relates to methods of using these compounds or agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells is necessary for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating the symptoms associated with such diseases, disabilities or conditions. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed.
Owner:MT SINAI SCHOOL OF MEDICINE
Catecholamine receptor modulation
Owner:YEDA RES & DEV CO LTD
Multi-media analysis for implementing advanced flight following and generating of projected tracks
ActiveUS9824591B1Enhance mobilizationAccurate predictionNavigational calculation instrumentsPosition fixationImage resolutionData source
A system and method are provided for monitoring, collecting and aggregating position information from multiple independent data sources to localize a position of an aircraft operating worldwide. The localized position information is provided to one or more end-users or stakeholders in a format for direct integration into one or more mapping and / or situational awareness display applications. Information is collected from a plurality of monitored data sources. Weighted values are applied to certain of the information collected from the plurality of data sources according to known or predictable / determinable static and / or dynamic accuracy errors and latencies of the information provided. A detailed analytic algorithm is applied to provide a probabilistic analysis that results in a resolution of a real-time, or near real-time, aircraft location, as well as an ability to accurately predict an aircraft location along a track at some future time.
Owner:ROCKWELL COLLINS INC
Method of treatment of vascular complications
InactiveUS20120058105A1Improve abilitiesPromote repairBiocideOrganic active ingredientsIGT - Impaired glucose toleranceCarbohydrate tolerance
The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and / or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and / or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and / or activity and / or level of TXNIP and / or an amount of a composition effective to induce, enhance or otherwise increase expression and / or activity and / or level of TRX is / are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and / or activity and / or level and / or TRX expression and / or activity and / or level for use in such therapeutic and prophylactic methods.
Owner:HEART RES INST LTD
Resonance modulator for diagnosis and therapy
InactiveUS20070049514A1Enhance immune functionEnhances resonance modulationBiocideElectrotherapyVoltage amplitudeResonance
A method and device are disclosed for monitoring and / or altering an immune function. The method uses a resonance modulating compound as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. The resonance modulator has electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of the resonance modulator are aryl hydrazones. The described aryl nitrohydrazones have the ability to interact with populations of cells with emergent behavioral characteristics associated with chemical, biological and radiation changes and injury. The disclosure also provides numerous other examples of resonance modulating agents, and provides attributes of these agents and assays for identifying additional resonance modulating agents.
Owner:DEKK TEC INC
Methods of utilizing the arrestin-2/stam-1 complex as a therapeutic target
InactiveUS20120059044A1Promote degradationLower Level RequirementsOrganic active ingredientsNervous disorderBiological bodyProtein molecules
Methods of utilizing the arrestin-2 / sTAM-1 complex as a therapeutic target. The methods include treating cells of a living organism to mediate an interaction between arrestin-2 and STAM-1 adapter protein molecules, wherein the interaction is characterized by the arrestin-2 adapter protein molecule directly binding to the STAM-2 adapter protein molecule. Pharmacological agents can be identified for therapeutic uses by determining whether the pharmacological agent disrupts the interaction between the arrestin-2 and STAM-1 adapter protein molecules.
Owner:LOYOLA UNIV OF CHICAGO
Structured lipid compositions and methods of formulation thereof
ActiveUS8206772B2Less availableTotal calories lowFermentationFood preparationTriglycerideWeight management
Lipid compositions comprising specific mixtures of edible synthetic triglycerides are provided that are useful in formulating food products having highly desirable dietary benefits. The novel lipid compositions allow simultaneous access to highly desirable dietary benefits such as delivery of calorie reduction, weight management, health benefits, or any combination thereof, and they also may be formulated trans-fatty acid free.
Owner:INTERCONTINENTAL GREAT BRANDS LLC
Compositions enriched for hox11+ stem cells and methods of preparing the same
InactiveUS20170106021A1Enhance mobilizationIncrease the number ofPeptide/protein ingredientsMicrobiological testing/measurementDiseaseMedicine
The invention features enriched Hox11+ stem cell compositions and methods of preparing and using the same. In particular, the enriched Hox11+ stem cell composition can be used for treating medical conditions, diseases, or disorders, for transplantation and transplantation therapy, and for cellular, tissue, or organ repair or regeneration.
Owner:THE GENERAL HOSPITAL CORP
Breakdown of fuel components and solvents in groundwater and contaminated soil
ActiveUS20180071800A1Enhance mobilizationImprove bioavailabilityCellsWater treatment parameter controlFenton reagentPollution soil
A system and method for remediation of polluted sites, implementing a combination of chemical and biological breakdown modes on the contaminating compounds. The system includes at least one reactor for production in situ of reagents required for the breakdown modes. The reactor includes at least three types of substantially independent electro-cells for production of Fenton reagents and dissolved oxygen. The method according to the invention includes utilizing at least one reactor which comprised of substantially independent electro-cells for producing reagents required for remediation of the polluted sites and a computerized controller loaded with data obtained from a site survey, measurements made by instruments and programmed sequence.The existing remediation techniques encounter in serious difficulties due to poor process control. Using the system according to the present invention allows control of the parameters and acceleration of the remediation process.
Owner:ELGRESSY ELIE
DME Fracing
InactiveUS20170218260A1Enhance mobilizationIncreasing gas and oil saturationFluid removalDrilling compositionChemistryEther
Herein is described a frac fluid comprising of di-methyl ether (DME) or a mixture of DME and propane to be used in hydraulic fracturing of underground formations.
Owner:CHAKRABARTY NEILIN
Crosslinking of swellable polymer with pei
ActiveUS20200095496A1Resist erosionLow toxicityFluid removalDrilling compositionPolymer scienceCross linker
Owner:UNIVERSITY OF KANSAS +1
Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists
InactiveUS20170348375A1Altered susceptibilityLonger treatmentOrganic active ingredientsNervous disorderBone Marrow Stem CellHaematological disorders
Haematopoietic stem cell mobilization is a process whereby haematopoietic stem cells are stimulated out of the bone marrow space. Before HSC can mobilize, they must be dislodged and released from the BM stem cell niche in which they reside and are retained by adhesive interactions. Accordingly, in an aspect of the present invention there is provided a method for enhancing dislodgement of HSC and their precursors and progenitors thereof from a BM stem cell binding ligand in vivo or ex vivo, said method comprising administering in vivo or ex vivo an effective amount of an antagonist of an a 9 integrin or an active portion thereof to the BM stem cell niche. Once mobilized to the peripheral blood (PB) the HSC may be collected for transplant. Methods which enhance mobilization of the HSC can also improve treatments of haematological disorders.
Owner:COMMONWEALTH SCI & IND RES ORG
Methods for hematopoietic precursor mobilization
Methods of modulating mobilization of cells from the bone marrow are provided. In a specific embodiment there is provided a method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a subject in need thereof, the method comprising: (a) administering to the subject an agent which downregulates an activity or expression of a coagulation factor or an effector thereof; and (b) harvesting the hematopoietic precursors from the peripheral blood.
Owner:YEDA RES & DEV CO LTD +1
Methods and products for manipulating hematopoietic stem cells
InactiveUS20080057579A1Enhance mobilizationEnhance transmigrationCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsBone marrow derived hematopoietic stem cellStem Cell Protein
The invention relates to methods for manipulating hematopoietic stem cells and related products. In one aspect the invention relates to the use of stem cell G-protein coupled receptor (SC-GPR) related compositions to identify bone marrow derived hematopoietic stem cells, to enhance mobilization of hematopoietic stem cells, to improve the efficiency of targeting cells to the bone marrow and / or to modulate hematopoietic cell function.
Owner:THE GENERAL HOSPITAL CORP
Stabilizer for a steerable drilling system
ActiveUS10711534B2Reduce the possibilityRaise the possibilityDrilling rodsDrilling casingsWell drillingClassical mechanics
Owner:WEATHERFORD TECH HLDG LLC
Bifunctional vectors allowing bcl11a silencing and expression of an Anti-sickling hbb and uses thereof for gene therapy of b-hemoglobinopathies
PendingUS20220160788A1Enhance gene therapyHigh expressionPeptide/protein ingredientsGenetic material ingredientsBeta thalassemiaCoboglobin
The #β-hemoglobinopathies #β-thalassemia (BT) and sickle cell disease (SCD) are the most frequent genetic disorders worldwide. These diseases are caused by mutations causing reduced or abnormal synthesis of the β-globin chain of the adult hemoglobin (Hb) tetramer. Here, the inventors intend to improve HSC-based gene therapy for β-thalassemia and SCD by developing an innovative, highly infectious LV vector expressing a potent anti-sickling β-globin transgene and a second biological function either increasing fetal γ-globin expression (for β-thalassemia and SCD). More particularly, the inventors have designed a novel lentivirus (LV), which carry two different functions: βAS3 gene addition and gene silencing. This last strategy allows the re-expression of the fetal γ-globin genes (HBG1 and HBG2) and production of the endogenous fetal hemoglobin (HbF). Elevated levels of HbF and HbAS3 (Hb tetramer containing βAS3-globin) will benefit the β-hemoglobinopathy phenotype by increasing the total amount of β-like globin that will: (i) reduce the alpha precipitates and improve the alpha / non alpha ratio in β-thalassemia, and (ii) reduce the sickling in SCD. This combined strategy will improve the β-hemoglobinopathy phenotype at a lower vector copy number (VCN) per cell compared to a LV expressing the βAS3 alone.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
Methods for increasing fetal hemoglobin content in eukaryotic cells and uses thereof for the treatment of hemoglobinopathies
PendingUS20220033856A1Increasing fetal hemoglobin contentInhibition of attachmentHydrolasesHaemoglobins/myoglobinsGenes mutationEucaryotic cell
The clinical severity of β-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal γ-globin chain production at adult age, a condition termed hereditary persistence of fetal hemoglobin (HPFH). Here, the inventors have compared the extent of fetal hemoglobin (HbF) de-repression following CRISPR / Cas9-mediated targeting of different regions of the HBG1 and HBG2 promoters in an adult erythroid cell line (HUDEP-2). They achieved a potent and pancellular HbF re-activation upon disruption of binding sites for γ-globin repressors located in both HBG1 and HBG2 genes. They validated these findings in Red Blood Cells (RBCs) derived from genome edited Sickle Cell Disease (SCD) patient hematopoietic stem / progenitor cells. Overall, this study identified a binding site for an HbF repressor as a novel and potent target for the treatment of β-hemoglobinopathies. Accordingly, the present invention relates to a method for increasing fetal hemoglobin content in a eukaryotic cell comprising the step of disrupting the binding site for Leukemia / lymphoma-related factor (LRF) in the HBG1 or HBG2 promoter.
Owner:UNIVERSITÉ PARIS CITÉ
Combined use of selective serotonin reuptake inhibitors and hematopoietic growth factors for treating hematopoietic diseases
PendingUS20220008514A1Convenient treatmentShorten the lengthPeptide/protein ingredientsAmine active ingredientsSerotonin reuptakePharmaceutical drug
The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.
Owner:UNIVERSITÉ PARIS CITÉ +5
Methods of utilizing the arrestin-2/STAM-1 complex as a therapeutic target
InactiveUS8691188B2Promote degradationLower Level RequirementsNervous disorderSugar derivativesBiological bodyProtein molecules
Methods of utilizing the arrestin-2 / sTAM-1 complex as a therapeutic target. The methods include treating cells of a living organism to mediate an interaction between arrestin-2 and STAM-1 adapter protein molecules, wherein the interaction is characterized by the arrestin-2 adapter protein molecule directly binding to the STAM-2 adapter protein molecule. Pharmacological agents can be identified for therapeutic uses by determining whether the pharmacological agent disrupts the interaction between the arrestin-2 and STAM-1 adapter protein molecules.
Owner:LOYOLA UNIV OF CHICAGO
Stabilizer for a steerable drilling system
ActiveUS20180298700A1Minimize the possibilityReduce the possibilityDrilling rodsDrilling casingsWell drillingOil and natural gas
This invention relates to a stabilizer (10) for a steerable drilling system, in particular for use in drilling directional boreholes for oil and gas extraction. There is provided a stabilizer (10) for a steerable drilling system having a first passageway (16) and a second passageway (18) at its outer surface, the passageways being helical and extending along the length of the stabilizer, the first and second passageways being oppositely-oriented, the first and second passageways intersecting one another, the stabilizer having a number of blades (22) between the passageways, the cross-sectional area of the first passageway being larger than the cross-sectional area of the second passageway. The asymmetric passageways enable the stabilizer designer to enhance the performance of the stabilizer during drilling and tripping.
Owner:WEATHERFORD TECH HLDG LLC
Methods and products for manipulating hematopoietic stem cells
InactiveUS20120201792A1Enhance transmigrationImprove efficiencyBiocidePeptide/protein ingredientsHematopoietic cellG protein-coupled receptor
The invention relates to methods for manipulating hematopoietic stem cells and related products. In one aspect the invention relates to the use of stem cell G-protein coupled receptor (SC-GPR) related compositions to identify bone marrow derived hematopoietic stem cells, to enhance mobilization of hematopoietic stem cells, to improve the efficiency of targeting cells to the bone marrow and / or to modulate hematopoietic cell function.
Owner:THE GENERAL HOSPITAL CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com